RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by
  • Главная
  • Выпуски
  • 2017 №1
  • Неинвазивные биомаркеры для оценки выраженности воспаления и фиброза печени при хроническом вирусном гепатите С: современное состояние проблемы

Неинвазивные биомаркеры для оценки выраженности воспаления и фиброза печени при хроническом вирусном гепатите С: современное состояние проблемы

И. В. Юркевич Комитет по здравоохранению Мингорисполкома
2017 №1 | В помощь практикующему врачу
Аннотация
Список литературы
Скачать полнотекстовую статью
В публикации рассмотрена классификация, клиническое значение и принципы использования современных неинвазивных биомаркеров, используемых для оценки выраженности воспаления и фиброза печени у пациентов с хроническим вирусным гепатитом С.
Ключевые слова:
биомаркеры, вирусный гепатит С, неинвазивная диагностика
Non-invasive biomarkers for assessment of expression of the inflammation and the fibrosis of the liver at the chronic viral hepatitis With:current state of the problem

In the publication classification, clinical value and the principles of use of the modern noninvasive biomarkers used for assessment of expression of an inflammation and a fibrosis of a liver at patients with a chronic viral hepatitis of Page is considered.

Keywords
biomarkers, a viral hepatitis With, non-invasive diagnostics
  • 1. Mohd Hanafiah, K. et al. Global epidemiology of hepatitis C virus infection: New estimates of agespecific antibody to HCV seroprevalence / K. Mohd Hanafiah [et al.] // Hepatology. - 2013. - Vol. 57, № 4. - P. 1333-1342.
  • 2. Messina, J. P. et al. Global distribution and prevalence of hepatitis C virus genotypes / J. P. Messina [et al.] // Hepatology (Baltimore, Md.). - 2015. - Vol. 61, № 1. - P. 77-87.
  • 3. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group Hepatology (Baltimore, Md.). - 1994. - Vol. 20, № 1, pt 1. - P. 15-20.
  • 4. Bedossa, P. Dargere, D. & Paradis, V. Sampling variability of liver fibrosis in chronic hepatitis C / P. Bedossa, D. Dargere, V. Paradis // Hepatology (Baltimore, Md.). - 2003. - Vol. 38, № 6. - P. 1449-1457.
  • 5. Castera, L. Noninvasive methods to assess liver disease in patients with hepatitis B or C / L. Castera // Gastroenterology. - 2012. - Vol. 142, № 6. - P. 1293-1302.e4.
  • 6. Chou, R. & Wasson, N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review / R. Chou, N. Wasson // Annals of Internal Medicine. - 2013. - Vol. 158, № 11. - P. 807-820.
  • 7. Valva, P. et al. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage / P. Valva [et al.] // World Journal of Gastroenterology. - 2016. - Vol. 22, № 4. - P. 1367-1381.
  • 8. Sebastiani, G., Gkouvatsos K. & Pantopoulos K. Chronic hepatitis C and liver fibrosis / G. Sebastiani, K. Gkouvatsos, K. Pantopoulos // World Journal of Gastroenterology. - 2014. - Vol. 20, № 32. - P. 11033-11053.
  • 9. Gressner, A. M. & Schafer, S. Comparison of sulphated glycosaminoglycan and hyaluronate synthesis and secretion in cultured hepatocytes, fat storing cells, and Kupffer cells / A. M. Gressner, S. Schafer // Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie. - 1989. - Vol. 27, № 3. - P. 141-149.
  • 10. Plevris, J. N. et al. Serum hyaluronan - a noninvasive test for diagnosing liver cirrhosis / J. N. Plevris [et al.] // European Journal of Gastroenterology & Hepatology. - 2000. - Vol. 12, № 10. - P. 1121-1127.
  • 11. Wong, V. S. et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection / V. S. Wong [et al.] // Journal of Viral Hepatitis. - 1998. - Vol. 5, № 3. - P. 187-192.
  • 12. Patel, K. et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C / K. Patel [et al.] // Journal of Gastroenterology and Hepatology. - 2003. - Vol. 18, № 3. - P. 253-257.
  • 13. Sanvisens, A. et al. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection / A. Sanvisens et al. // Journal of Viral Hepatitis. - 2009. - Vol. 16, № 7. - P. 513-518.
  • 14. Valva, P. et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection / P. Valva [et al.] // PloS One. - 2011. - Vol. 6, № 8. - P. E23218.
  • 15. Halfon, P. et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus / P. Halfon [et al.] // Comparative Hepatology. - 2005. - Vol. 4, - P. 6.
  • 16. Resino, S. et al. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? / S. Resino [et al.] // BMC infectious diseases. - 2010. - Vol. 10, - P. 244.
  • 17. Gressner, O. A. Weiskirchen, R. & Gressner, A. M. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality / O. A. Gressner, R. Weiskirchen, A. M. Gressner // Journal of Cellular and Molecular Medicine. - 2007. - Vol. 11, № 5. - P. 1031-1051.
  • 18. Veidal, S. S. et al. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats / S. S. Veidal [et al.] // Fibrogenesis & Tissue Repair. - 2010. - Vol. 3, № 1. - P. 5.
  • 19. Baranova, A. et al. Non-invasive markers for hepatic fibrosis / A. Baranova [et al.] // BMC gastroentero logy. - 2011. - Vol. 11, - P. 91.
  • 20. Leroy, V. et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid / V. Leroy [et al.] // The American Journal of Gastroenterology. - 2004. - Vol. 99, № 2. - P. 271-279.
  • 21. Zheng, M. et al. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis / M. Zheng [et al.] // World Journal of Gastroenterology. - 2002. - Vol. 8, № 6. - P. 1073-1076.
  • 22. Saitou, Y. et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease / Y. Saitou [et al.] // World Journal of Gastroenterology. - 2005. - Vol. 11, № 4. -P. 476-481.
  • 23. Murawaki, Y. et al. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C / Y. Murawaki [et al.] // Journal of Gastroenterology. - 2001. - Vol. 36, № 6. - P. 399-406.
  • 24. Kropf, J. Gressner, A. M. & Negwer, A. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases / J. Kropf, A. M. Gressner, A. Negwer // Clinical Chemistry. - 1988. - Vol. 34, № 10. - P. 2026-2030.
  • 25. Korner, T. Kropf, J. & Gressner, A. M. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value / T. Korner, J. Kropf, A. M. Gressner // Journal of Hepatology. - 1996. - Vol. 25, № 5. - P. 684-688.
  • 26. Misaki, M. et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease / M. Misaki [et al.] // Clinical Chemistry. - 1990. - Vol. 36, № 3. - P. 522-524.
  • 27. Torok, N. J. Recent advances in the pathogenesis and diagnosis of liver fibrosis / N. J. Torok // Journal of Gastroenterology. - 2008. - Vol. 43, № 5. - P. 315-321.
  • 28. Friedman, S. L. Liver fibrosis - from bench to bedside / S. L. Friedman // Journal of Hepatology. -2003. - Vol. 38, suppl. 1, - P. S38-53.
  • 29. Friedman, S. L. Mechanisms of hepatic fibrogenesis / S. L. Friedman // Gastroenterology. - 2008. - Vol. 134, № 6. - P. 1655-1669.
  • 30. Goto, T. et al. Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells / T. Goto [et al.] // Pathophysiology: The Official Journal of the International Society for Pathophysiology. - 2004. - Vol. 11, № 3. - P. 153-158.
  • 31. Walsh, K. M. et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis / K. M. Walsh [et al.] // Digestive Diseases and Sciences. - 1999. - Vol. 44, № 3. - P. 624-630.
  • 32. Macfas, J. et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients / J. Macias [et al.] // HIV medicine. - 2011. - Vol. 12, № 1. - P. 14-21.
  • 33. Badra, G. et al. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metallopro-teinase-1 in chronic hepatitis C patients / G. Badra [et al.] // Acta Microbiologica Et Immunologica Hungarica. - 2010. - Vol. 57, № 1. - P. 29-42.
  • 34. Parkes, J. et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C / J. Parkes [et al.] // Journal of Viral Hepatitis. - 2011. - Vol. 18, № 1. - P. 23-31.
  • 35. Tran, A. et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease / A. Tran [et al.] // European Journal of Gastroenterology & Hepatology. - 2000. - Vol. 12, № 9. - P. 989-993.
  • 36. Nelson, D. R. [et al.] Transforming growth factorbeta 1 in chronic hepatitis C / D. R. Nelson [et al.] // Journal of Viral Hepatitis. - 1997. - Vol. 4, № 1. -P. 29-35.
  • 37. Rallon, N. I. et al. Elevated TGF-P1 levels might protect HCV/HIV-coinfected patients from liver fibrosis / N. I. Rallon [et al.] // European Journal of Clinical Investigation. - 2011. - Vol. 41, № 1. - P. 70-76.
  • 38. Soliman, G. M. M. et al. The role of plasma transforming growth factor beta-1 in the development of fibrosis in patient with HCV related steatohepatitis / G. M. M. Soliman [et al.] // Journal of the Egyptian Society of Parasitology. - 2010. - Vol. 40, № 3. - P. 759-772.
  • 39. Patel, K. et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C / K. Patel [et al.] // Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association. -2008. - Vol. 6, № 2. - P. 242-247.
  • 40. Christensen, C. et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients / C. Christensen [et al.] // Journal of Viral Hepatitis. - 2006. - Vol. 13, № 10. - P. 652-658.
  • 41. Zaman, A. et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients / A. Zaman [et al.] // The American Journal of Medicine. - 2007. - Vol. 120, № 3. - P. 280.e9-14.
  • 42. Cales, P. et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD / P. Cales [et al.] // Journal of Hepatology. - 2009. - Vol. 50, № 1. - P. 165-173.
  • 43. Cales, P. et al. A novel panel of blood markers to assess the degree of liver fibrosis / P. Cales et al.] // Hepatology (Baltimore, Md.). - 2005. - Vol. 42, № 6. - P. 1373-1381.
  • 44. Leroy, V. et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C / V. Leroy [et al.] // Journal of Hepatology. - 2007. - Vol. 46, № 5. - P. 775-782.
  • 45. Zarski, J.-P. et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study / J.-P. Zarski [et al.] // Journal of Hepatology. - 2012. - Vol. 56, № 1. - P. 55-62.
  • 46. Schiavon, L. de L. Narciso-Schiavon, J. L. & de Carvalho-Filho, R.J. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C / L. de L. Schiavon, J. L. Narciso-Schiavon, R. J. de Carvalho-Filho // World Journal of Gastroenterology. - 2014. - Vol. 20, № 11. -P. 2854-2866.
  • 47. Adams, L. A. et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection / L. A. Adams [et al.] // Clinical Chemistry. - 2005. - Vol. 51, № 10. - P. 1867-1873.
  • 48. Becker, L. et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States / L. Becker [et al.] // Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association. - 2009. - Vol. 7, № 6. - P. 696-701.
  • 49. Martinez, S. M. et al. Noninvasive assessment of liver fibrosis / S. M. Martinez [et al.] // Hepatology (Baltimore, Md.). - 2011. - Vol. 53, № 1. - P. 325-335.
  • 50. Rosenberg, W. M. C. et al. Serum markers detect the presence of liver fibrosis: a cohort study / W. M. C. Rosenberg [et al.] // Gastroenterology. - 2004. -Vol. 127, № 6. - P. 1704-1713.
  • 51. Kelleher, T. B. et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index / T. B. Kelleher [et al.] // Journal of Hepatology. - 2005. - Vol. 43, № 1. - P. 78-84.
  • 52. Wai, C.-T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C / C.-T. Wai [et al.] // Hepatology (Baltimore, Md.). - 2003. - Vol. 38, № 2. - P. 518-526.
  • 53. Teare, J. P. et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis / J. P. Teare [et al.] // Lancet (London, England). - 1993. - Vol. 342, № 8876. - P. 895-898.
  • 54. Naveau, S. et al. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest / S. Naveau [et al.] // Digestive Diseases and Sciences. - 1994. - Vol. 39, № 11. - P. 2426-2432.
  • 55. Forns, X. et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model / X. Forns [et al.] // Hepatology (Baltimore, Md.). - 2002. - Vol. 36, № 4 pt 1. - P. 986-992.
  • 56. Imbert-Bismut, F. et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study / F. Imbert-Bismut [et al.] // Lancet (London, England). - 2001. - Vol. 357, № 9262. - P. 1069-1075.
  • 57. Myers, R. P. et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B / R. P. Myers [et al.] // Journal of Hepatology. - 2003. - Vol. 39, № 2. - P. 222-230.
  • 58. Parise, E. R. et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection / E.R. Parise [et al.] // Liver International: Official Journal of the International Association for the Study of the Liver. - 2006. - Vol. 26, № 9. - P. 1095-1099.
  • 59. Shaikh, S. et al. Validation of three non-invasive markers in assessing the severity of liver fibrosis in chronic hepatitis C / S. Shaikh [et al.] // Journal of the College of Physicians and Surgeons-Pakistan: JCPSP. - 2009. - Vol. 19, № 8. - P. 478-482.
  • 60. Giannini, E. et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotrans-ferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease / E. Giannini [et al.] // Archives of Internal Medicine. - 2003. - Vol. 163, № 2. - P. 218-224.
  • 61. Sebastiani, G. & Alberti, A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy / G. Sebastiani, A. Alberti // World Journal of Gastroenterology. - 2006. - Vol. 12, № 23. - P. 3682-3694.
  • 62. Sebastiani, G. & Alberti, A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? / G. Sebastiani, A. Alberti // Journal of Viral Hepatitis. - 2012. - Vol. 19, suppl. 1. - P. 18-32.
  • 63. Sebastiani, G. et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C / G. Sebastiani [et al.] // Journal of Hepatology. - 2006. - Vol. 44, № 4. - P. 686-693.
  • 64. Lin, Z.-H. et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis / Z.-H. Lin [et al.[ // Hepatology (Baltimore, Md.). - 2011. - Vol. 53, № 3. - P. 726-736.
  • 65. Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection / R. K. Sterling [et al.] // Hepatology (Baltimore, Md.). - 2006. - Vol. 43, № 6. -P. 1317-1325.
  • 66. Vallet-Pichard, A. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest / A. Vallet-Pichard [et al.] // Hepatology (Baltimore, Md.). - 2007. - Vol. 46, № 1. - P. 32-36.
  • 67. Guzelbulut, F. et al. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C / F. G uzelbulut [et al.] // The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology. - 2011. - Vol. 22, № 3. - P. 279-285.
  • 68. Schiavon, L. L. et al. Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients / L. L. Schiavon [et al.] // Hepatology (Baltimore, Md.). - 2007. - Vol. 45, № 1. - P. 257-258.
  • 69. Adler, M. et al. The predictive value of FIB-4 versus FibroTest, APRI, Fibrolndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases / M. Adler [et al.] // Hepatology (Baltimore, Md.). - 2008. - Vol. 47, № 2. - P. 762-763; author reply 763.
  • 70. Amorim, T. G. F. et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C / T. G. F. Amorim [et al.] // Annals of Hepatology. - 2012. - Vol. 11, № 6. - P. 855-861.
  • 71. Imbert-Bismut, F. et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors / F. Imbert-Bismut et al. // Clinical Chemistry and Laboratory Medicine. - 2004. - Vol. 42, № 3. - P. 323-333.
  • 72. Friedrich-Rust, M. et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis / M. Friedrich-Rust [et al.] // BMC gastroenterology. - 2010. - Vol. 10. - P. 103.
  • 73. Poynard, T. et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin / T. Poynard [et al.] // Hepatology (Baltimore, Md.). - 2003. - Vol. 38, № 2. - P. 481-492.
  • 74. Poynard, T. et al. ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure / T. Poynard [et al.] // Gastroenterologie Clinique Et Biologique. - 2010. - Vol. 34, № 6-7. - P. 388-396.
  • 75. Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon / A. M. Di Bisceglie [et al.] // The New England Journal of Medicine. - 2008. - Vol. 359, № 23. - P. 2429-2441.
  • 76. Poynard, T. et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies / T. Poynard [et al.] // Antiviral Therapy. - 2010. - Vol. 15, № 4. - P. 617-631.
  • 77. Poynard, T. et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers / T. Poynard [et al.] // PloS One. - 2008. - Vol. 3, № 12. - P. E3857.
  • 78. Coco, B. et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases / B. Coco [et al.] // Journal of Viral Hepatitis. - 2007. - Vol. 14, № 5. - P. 360-369.
  • 79. Bourliere, M. et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies / M. Bourliere et al. // Journal of Viral Hepatitis. - 2006. - Vol. 13, № 10. - P. 659-670.
  • 80. Castera, L. et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C / L. Castera [et al.] // Journal of Hepatology. - 2010. - Vol. 52, № 2. - P. 191-198.
  • 81. Boursier, J. et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive / J. Boursier [et al.] // Hepatology (Baltimore, Md.). - 2012. - Vol. 55, № 1. - P. 58-67.
  • 82. Fischer, R. Baumert, T. & Blum, H.-E. Hepatitis C virus infection and apoptosis / R. Fischer, T. Baumert, H.-E. Blum // World Journal of Gastroenterology. - 2007. - Vol. 13, № 36. - P. 4865-4872.
  • 83. Silberstein, E. et al. HCV-Mediated Apoptosis of Hepatocytes in Culture and Viral Pathogenesis / E. Silberstein [et al.] // PloS One. - 2016. - Vol. 11, № 6. - P. E0155708.
  • 84. Kountouras, J., Zavos C. & Chatzopoulos D. Apoptosis in hepatitis C / J. Kountouras, C. Zavos, D. Chatzopoulos // Journal of Viral Hepatitis. - 2003. -Vol. 10, № 5. - P. 335-342.
  • 85. Valva, P. et al. Distinctive intrahepatic characteristics of paediatric and adult pathogenesis of chronic hepatitis C infection / P. Valva [et al.] // Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. - 2014. - Vol. 20, № 12. - P. O998-1009.
  • 86. Musso, G. et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity / G. Musso [et al.] // Annals of Medicine. - 2011. - Vol. 43, № 8. - P. 617-649.
  • 87. Bantel, H. et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury / H. Bantel [et al.] // Hepatology (Baltimore, Md.). - 2004. - Vol. 40, № 5. - P. 1078-1087.
  • 88. Seidel, N. et al. The extent of liver steatosis in chronic hepatitis С virus infection is mirrored by caspase activity in serum / N. Seidel [et al.[ // Hepatology (Baltimore, Md.). - 2005. - Vol. 42, № 1. - P. 113-120.
  • 89. Papatheodoridis, G. V. et al. Serum apoptotic caspase activity in chronic hepatitis С and nonalcoholic Fatty liver disease / G. V. Papatheodoridis [et al.] // Journal of Clinical Gastroenterology. - 2010. - Vol. 44, № 4. - P. E87-95.
  • 90. Canbay, A., Friedman S. & Gores G. J. Apoptosis: the nexus of liver injury and fibrosis / A. Canbay, S. Friedman, G. J. Gores // Hepatology (Baltimore, Md.). - 2004. - Vol. 39, № 2. - P. 273-278.
  • 91. El Bassiouny, A. E. I. et al. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma / A. E. I. El Bassiouny [et al.] // Medscape Journal of Medicine. - 2008. - Vol. 10, № 6. - P. 130.
  • 92. Zekri, A.-R. N. etal. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis С virus genotype-4 / A.-R.N. Zekri [et al.] // Comparative Hepatology. - 2010. - Vol. 9, № 1. - P. 1.
  • 93. Toyoda, M. et al. Role of serum soluble Fas / soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis С / M. Toyoda [etaI.] // Liver. - 2000. - Vol. 20, № 4. - P. 305-311.
  • 94. Kakiuchi, Y. et al. Circulating soluble Fas levels in patients with hepatitis С virus infection and interferon therapy / Y. Kakiuchi [et al.] // Journal of Gastroenterology. - 2004. - Vol. 39, № 12. - P. 1189-1195.
  • 95. Valva, P. et al. Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children / P. Valva [et al.] // PloS One. - 2013. - Vol. 8, № 1. - P. E53519.
  • 96. Liedtke, C. &Trautwein C. The role ofTNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer / C. Liedtke, C. Trautwein // European Journal of Cell Biology. - 2012. - Vol. 91, № 6-7. - P. 582-589.
  • 97. Eguchi, A. Wree, A. & Feldstein A. E. Biomarkers of liver cell death / A. Eguchi, A. Wree, A. E. Feldstein // Journal of Hepatology. - 2014. - Vol. 60, № 5. - P. 1063-1074.